FDA approves Novartis drug as first-line treatment for breast cancer

(Reuters) - Novartis AG said on Monday that the U.S. Food and Drug Administration had approved the company's experimental drug, kisqali, as a first-line treatment for a type of breast cancer in postmenopausal women, in combination with another breast cancer drug.